Citation Impact
Citing Papers
The resistance mechanisms of proteasome inhibitor bortezomib
2013
A practical review on carfilzomib in multiple myeloma
2016
Multiple myeloma
2014
Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma
2015
Inflammation and tumor progression: signaling pathways and targeted intervention
2021 Standout
The use of novel agents in the treatment of relapsed and refractory multiple myeloma
2009
The mechanism of action, pharmacokinetics, and clinical efficacy of carfilzomib for the treatment of multiple myeloma
2013
Proteasome Inhibitors with Photocontrolled Activity
2014 StandoutNobel
Modulation of NF-κB Signaling as a Therapeutic Target in Autoimmunity
2015
Rutin Attenuates Carfilzomib-Induced Cardiotoxicity Through Inhibition of NF-κB, Hypertrophic Gene Expression and Oxidative Stress
2015
Marine-Derived Angiogenesis Inhibitors for Cancer Therapy
2013
Inhibition of NGLY1 Inactivates the Transcription Factor Nrf1 and Potentiates Proteasome Inhibitor Cytotoxicity
2017 StandoutNobel
Marine natural products
2015 Standout
Neue Ziele für die Photopharmakologie
2016 StandoutNobel
Combination therapy in combating cancer
2017 Standout
Flavonoids as Potential Anti-Inflammatory Molecules: A Review
2022 Standout
Natural product and natural product derived drugs in clinical trials
2014 Standout
Emerging Targets in Photopharmacology
2016 StandoutNobel
Works of Sandra Wear being referenced
Phase 1 Clinical Evaluation of Twice-Weekly Marizomib (NPI-0052), a Novel Proteasome Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM)
2011
Phase 1 Clinical Trial of NPI-0052, a Novel Proteasome Inhibitor in Patients with Multiple Myeloma
2008
An open‐label, single‐arm, phase 2 study of single‐agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib
2012